2076 - Wahroonga - Sydney Adventist Hospital (COMPLETED)2485 - Tweed Heads - The Tweed Hospital (COMPLETED)2640 - Albury - Border Medical Oncology Research Unit (COMPLETED)

3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (COMPLETED)

QLD4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)

NCT02861573

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

NCT02582697

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)

2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)

3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)

NZ.9016 - Dunedin - Dunedin Hospital (WITHDRAWN)

ACTRN12625001151426

Not Applicable

Feasibility of delivering High Dose Palliative Radiotherapy in patients with Metastatic malignancy (HD-PRiMe)

ACTRN12625000971437

Dose Optimisation and PSMA Receptor intensification with 177Lu-PSMA Therapy in Patients Diagnosed with Metastatic Castrate Resistant Prostate Cancer : A Randomised Phase II trial: OPTIMAL-PSMA

ACTRN12625000487415

Not Applicable

Efficacy of toxicity reduction with urethra sparing stereotactic ablative body radiation therapy for prostate cancer, assessing toxicities and quality of life in patients with intermediate risk prostate cancer. (TRUST)

ACTRN12625000484448

Not Applicable

Investigating the use of Stereotactic Ablative Body Radiation (SABR) Dose Escalation and Tri-Modality Treatment in Muscle-Invasive Bladder Cancer (MIBC) on local disease control outcomes. (Bladder-Boost)

ACTRN12625000259448

Not Applicable

Stereotactic ablative body radiation therapy with nodal irradiation of prostate cancer, assessing toxicities and quality of life in patients with high risk and/or node positive prostate cancer. (SNIPER)

ACTRN12625000224426

Not Applicable

Salvage sTereotactic Ablative radiotherapy for patients with Recurrent prostate cancer With Androgen suppression and Rectal Spacer, assessing toxicity and quality of life (STARWARS)

ACTRN12625000203459

An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (ENG19)

ACTRN12625000198426

Not Applicable

2-fraction Stereotactic ultra-HypOfractionated radiation Therapy of the proState, assessing toxicities and quality of life in patients with intermediate risk prostate cancer (2SHOTS)

ACTRN12624001458527

Randomised Phase 2 study of sphingosine kinase inhibitor (opaganib) in addition to darolutamide in people with poor prognostic metastatic castration resistant prostate cancer (mCRPC) based on a companion circulating lipid biomarker, PCPro (ANZUP2205) (DARO-LIPID)

ACTRN12624001188527

G-DISCO: A Phase 1 study of feasibility, safety and tolerability of synchronous intravesical administration of gemcitabine and docetaxel - ANZUP 2403.

ACTRN12624001123538

A Multicentre, Open-label, Interventional, Repeated Dose Escalation/De-escalation Phase I Trial to Determine the Optimal Biological Dose, and Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of Actinium (225Ac) Ibu-DAB-PSMA for the Treatment of PSMA-positive Progressive Metastatic Castration Resistant Prostate Cancer (ITM-2221-01CT)

ACTRN12624001119583

Not Applicable

Transperineal prostate biopsy under local anaesthetic in adults with suspected or confirmed prostate cancer: an analysis of cost, efficacy and patient tolerability in Australia

ACTRN12624000644561

Not Applicable

A randomised controlled trial comparing animation-based with written patient information for educating patients about robotic-assisted radical prostatectomy

ACTRN12624000582550

Evaluating the efficacy of bipolar androgen therapy in extending metastasis-free survival in patients with M0 castrate-resistant prostate cancer with prostate specific antigen progression but not radiological or clinical progression on darolutamide (WOMBAT) - ANZUP 2201

ACTRN12624000110583

Not Applicable

SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (SOCRATES-PILOT)

ACTRN12623001072606

A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC) (LuCape)

ACTRN12623000919617

A clinical trial exploring MR guided adaptive stereotactic radiotherapy boost to the prostate combined with stereotactic radiotherapy to the whole pelvis (MR-PROTEUS)

ACTRN12623000902695

Not Applicable

MRI Guided Stereotactic Focal Ablation of Prostate Cancer investigating feasibility, Toxicity and Patient Reported Outcomes. (MR-Ablate)

ACTRN12623000216617

A pilot, feasibility study of 177Lu-DOTA-Rosopatamab (TLX591) therapy in castrate resistant prostate adenocarcinoma patients showing progression on radioligand therapy using PSMA small molecule ligands (RESCUE)

ACTRN12623000160639

A Randomized, Open-Label, Phase 2 Study of Darolutamide as Single Agent or in Combination with EPI-7386 as a Neoadjuvant Treatment for Patients Undergoing Prostatectomy for Localized Prostate Cancer (DaSCENT)

ACTRN12623000073606

A Single-Arm, Open-Label, Prospective, Phase 0 Trial Evaluating the Safety and Efficacy of Salvage 177Lu-PSMA-I&T in Prostate Specific Antigen (PSA) Biochemical Failure After Radical Prostatectomy for High-Risk Prostate Cancer (SLAP-trial)

ACTRN12622001478707

Not Applicable

A multi-centre, randomised phase 2 clinical trial of early salvage radiotherapy versus surveillance on the incidence of biochemical recurrence after radical prostatectomy for men with prostate cancer, incorporating clinical and imaging-based risk stratification. (DIPPER)

ACTRN12622001378718

Phase I/IIa Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma (TheraPb – Phase I/II) (TheraPb-phase-I-II)

ACTRN12622001003763

A multi-centre, open label phase 2 trial investigating the effect of evolocumab in addition to chemotherapy or androgen receptor signalling inhibitor therapy on the circulating lipid profile of men with metastatic castration-resistant prostate cancer (X22-0072)

ACTRN12621000611820

Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction (PICAASO)

ACTRN12621000227897

Not Applicable

Feasibility of Magnetic Resonance Imaging guided stereotactic reirradiation in patients who have previously received radiation for prostate cancer and have biochemical and local recurrence of cancer within the prostate (PRIUS-MR)

ACTRN12618001667202

A Randomised Trial of External Beam Radiation Therapy (EBRT) Alone versus EBRT in Combination with 177Lu-PSMA Theranostic in Patients with Biochemically Recurrent Prostate Cancer (to determine the proportion of participants in each group with a 50% decline in PSA through to the end of the trial) - a phase 3 study (TARGET)

ACTRN12616001021460

A Phase I trial of Sodium Valproate/MetformIn Combination as neoadjuvant therapy for ProstatE canceR (VIPER-1-trial)

ACTRN12613000774729

Bladder Adaptive Radiotherapy (BART) Trial - From Bladder Online Adaptive Radiotherapy (BOLART) to BART: A study on the feasibility of BART (Where less is perhaps more)

NCT07000149

A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (eVOLVE-RCC02)

NCT06909825

A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) (FPI-2265-203)

NCT05805501

A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (BO43936)

NCT05712356

A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)

NCT04122976

Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients (DAROL)

NCT02643511

Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer (STGAF)

NCT02613819

Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial (FASTRACK II) (FASTRACK-II)

ACTRN12621000747820

TaxAdapt: Feasibility, acceptability and safety of adaptive dosing of docetaxel in men with metastatic castrate-resistant prostate cancer

androgen axis	30%
AR	27%
PD-1/PD-L1	17%
CYP17A1	17%
PD-1	16%
PSMA	14%
PARP	7%
oestrogen axis	6%
KIT	5%
PD-L1	5%
MET	4%
VEGFR	4%
Nectin4	4%
STEAP1	4%
PARP1-selective	3%
AXL	3%
RET	3%
ROS1	3%
VEGFR2	3%
HIF2a	3%
CYP11A1	3%
ERBB2	3%
VEGF	3%
CTLA4	2%
TIGIT	2%
EZH2	2%
B7H3	2%
ER	2%
FGFR3	2%
KLK2	2%
EGFR	2%
ERBB3	2%
KAT6	2%
LHRH	2%
CDK4	2%
CDK4 selective	2%
PDGFR	2%
BCR-ABL1	2%
PDGFRA	2%
SRC	2%
YES1	2%
GnRH	2%
VEGFA	1%
MER	1%
hGIIA-vimentin	1%
GPC3	1%
CDKN1A	1%
PSMA∕STEAP1	1%
STEAP2	1%
CDK2	1%
STING	1%
DNA-dependent protein kinase	1%
PRC2 complex	1%
IL-2	1%
CCR8	1%
CDK6	1%
TP53	1%
TP53 Y220C	1%
sphingosine kinase-2	1%
HMG-CoA reductase	1%
antiandrogen,AR NTD	1%
PCSK9	1%
HDAC	1%
LAG3	1%

ARTICANZ - Beta (ver 0.91)

Search results

Prostate and Urogenital

Filters